Background. Natural infection with Bordetella pertussis is thought to result in 4-20 years of immunity against subsequent symptomatic pertussis infection. However, these estimates are based on studies in unvaccinated or whole-cell pertussis-vaccinated children. We conducted a population-based study of pertussis infection and reinfection during a 5-year period in California in an cohort vaccinated exclusively with acellular pertussis (aP) vaccine.
Pertussis is a cough illness caused by infection with Bordetella pertussis. Whole-cell pertussis (wP) vaccines were introduced in the United States in the 1940s and 1950s and led to a large decline in the number of annual pertussis cases reported in the United States [1] . Owing to concern about adverse events associated with the use of wP vaccines, acellular pertussis (aP) vaccines were developed and licensed in the 1990s for the fourth and fifth doses of the diphtheria, tetanus, and pertussis vaccination series and have been recommended for the entire 5-dose series in the United States since 1997 [1] . In the United States, children receive a 5-dose series of diphtheria and tetanus toxoids and aP (DTaP) vaccine at ages 2, 4, 6, and 15-18 months and 4-6 years. Three doses of DTaP before the sixth month of life are necessary to protect infants from pertussis infection.
For many decades, it was thought that immunity after natural infection with B. pertussis was effectively lifelong [2] . This hypothesis was based primarily on epidemiological studies conducted during the prevaccine era [2, 3] . In the postvaccine era, 1 case series and 1 subanalysis from a pertussis vaccine clinical trial in Senegal documented recurrent cases of symptomatic pertussis infection in children. In that trial, 210 cases of recurrent pertussis were identified in which the mean interval between the 2 infections was 7.1 (range, 6.6-7.6) years in unvaccinated children and 5.1 (4.5-5.7) years in vaccinated children [4] . Unfortunately, diagnosis was not confirmed using laboratory evidence of B. pertussis infection, and detailed information about which pertussis vaccine each child had received (aP vs wP) was not included. In addition to the Senegal study, a case series from the Netherlands described recurrent pertussis infections in 4 children who visited an allergy clinic; the mean interval between the 2 pertussis episodes in those children ranged from 3.5 to 12 years [5] . Based on that study and 4 other studies in adults, a review published in 2005 concluded that infection-acquired immunity against symptomatic pertussis wanes after 4-20 years [6] .
Because of the lack of data about the occurrence of recurrent pertussis infections in children immunologically primed with aP vaccines, we conducted a surveillance-based study of recurrent pertussis infection in children in California during a 5-year period. To our knowledge, ours is the first surveillance-based study of recurrent pertussis infections in children and it is the first study of recurrent pertussis in children exclusively vaccinated with aP pertussis vaccine. We describe cases of recurrent pertussis infection among California children and discuss a number of hypotheses that may explain why recurrent pertussis infections occur.
METHODS

Pertussis Disease Case Definition and Classification
Clinicians and laboratory personnel are required to report cases of pertussis in California residents to local public health departments. Additional surveillance data are collected through a variety of methods, including patient and caregiver interviews, immunization registry reviews, and laboratory and medical record abstraction. Cases are subsequently reported to the California Department of Public Health and classified as confirmed, probable, or suspected. Confirmed and probable cases are defined in accordance with the 2010 and 2014 criteria from the Council of State and Territorial Epidemiologists [7] . Suspected cases were characterized by either (1) an acute cough illness of any duration along with detection of B. pertussis-specific nucleic acid by polymerase chain reaction (PCR) or (2) an acute cough illness of any duration and ≥1 of the following: paroxysms of cough, inspiratory "whoop, " or posttussive vomiting [8] .
The suspected case classification is unique to California and was created to capture patients with pertussis who met the criteria for a confirmed case but had not coughed ≥2 weeks at the time of interview. Owing to the large number of pertussis cases reported annually in California, local health departments are unable to conduct repeated follow-up interviews with every patient to determine the final duration of cough illness. In addition, infants with fatal pertussis may die <2 weeks after symptom onset. The new 2014 criteria from the Council of State and Territorial Epidemiologists were updated to specifically address this limitation and now no longer require evidence of ≥2 weeks of cough in their infant definition.
Recurrent Pertussis Case Definition and Case Identification
A recurrent pertussis case was defined as 2 distinct episodes of confirmed, probable, or suspected pertussis (2 separate cough episodes separated by at least ≥30 days during which no symptoms were documented), in a child <18 years of age. The analysis was limited to children to specifically evaluate individuals exclusively vaccinated with aP vaccines and owing to low rates of pertussis case reporting among adults. All reported pertussis incidents in children with symptom onset between 1 January 2010 and 31 December 2015 were reviewed, and those with matching birth date, first name, and last name were identified. All matching cases were reviewed and excluded if they were found to be duplicate records or did not meet the recurrent pertussis case definition (eg, no clear evidence of recovery between episodes).
Vaccination records were gathered and verified. All children included in this review were vaccinated exclusively with aP vaccines. Demographic, clinical, and laboratory characteristics were described for both illness episodes for cases meeting the inclusion criteria.
RESULTS
Of 26 259 reported pertussis cases in children <18 years of age at illness onset, 36 cases with >1 report with matching birth date, first name, and last name were identified. After further review, 5 cases were excluded because they were duplicate records for the same pertussis episode, 2 were excluded because 1 of the 2 pertussis episodes did not meet the case definition for pertussis, and 2 were excluded because there was no clear documentation that the child was symptom free between the 2 episodes, making it difficult to distinguish between a recurrent case and simply the continuation of symptoms from the first infection. In total, 27 children with 2 distinct episodes of pertussis were included in this study.
Age, sex, race/ethnicity, vaccination information, PCR results, cough duration, and classic pertussis symptoms are presented in Table 1 . Eleven patients (41%) were female, 14 (52%) were Hispanic, and 11 (41%) were white, non-Hispanic. Recurrent pertussis cases occurred among all pediatric age groups. Five infants (22%) were <6 months of age at the time of their first episode; 4 were completely unvaccinated, and 1 had received 1 dose of DTaP. Of the 22 patients >6 months of age, 21 were vaccinated with ≥3 doses of DTaP vaccine at the time of their first symptomatic pertussis episode and were considered to be aP vaccine primed (vaccinated with aP vaccine before natural infection), and 1 child was unvaccinated owing to parental refusal.
Of the 27 recurrent cases, all had PCR confirmation of pertussis infection for ≥1 episode, and 22 (81%) had PCR confirmation for both pertussis episodes. Of the 5 episodes without laboratory confirmation, 2 were epidemiologically linked to a laboratory-confirmed case, and the other 3 met the clinical case definition for pertussis.
The majority of cases had ≥1 incident with onset in 2014 or 2015 during a major pertussis epidemic in California [9] . The 27 recurrent cases occurred in 13 counties across California: Contra Costa (1 case), Los Angeles (3), Marin (1) Mono (1), Napa (1), Orange (1), San Bernardino (1), San Diego (12), San Francisco (2), San Mateo (1), Santa Clara (1), Solano (1), and Ventura (1) .
Four children visited the emergency room for their pertussis illness: 1 during the first pertussis episode, 2 during the second episode, and 1 for both episodes. Three additional patients were hospitalized; 2 were previously healthy, unvaccinated infants <2 months of age who were admitted, evaluated, and discharged after 1 night in the hospital, and the third was a fully vaccinated Table 1 
years
Abbreviations: A, apnea; C, cyanosis; F, female; M, male; P, paroxysmal cough; PCR, polymerase chain reaction; V, vomiting; W, whoop.
2-year-old who had a previous confirmed episode of pertussis at age 8 months. This patient had a complex medical history, including a congenital heart abnormality and developmental delay. None of the children had an immunocompromising condition diagnosed. Eleven (20%) of the second episodes occurred within 1 year of the first episode and 17 (63%) occurred within 2 years. Thirteen children (48%) had not received any vaccine between their first and second pertussis episodes. Among the 48 pertussis episodes occurring in a child >6 months of age, 13 (27%) occurred within 1 year of the child's most recent pertussis vaccination.
DISCUSSION
Recurrent cases of pertussis infection are extremely rare. Based on our surveillance data, approximately 0.1% of children who were infected with pertussis experienced a clinically significant second episode of pertussis within 4 years. To our knowledge, this is the first population-based study of recurrent pertussis cases in an aP-vaccinated cohort.
Recurrent cases of pertussis were identified in children of all ages. As expected, a substantial number of first pertussis episodes (19%) occurred among infants <6 months of age, which is expected given that infants are not considered protected until after receipt of 3 doses of DTaP vaccine, typically at 6 months of age. However, second pertussis episodes occurred among children of all ages with no predominant age. Almost half (44%) of the recurrent cases were reported in San Diego County. This may be the result of increased recognition of pertussis by clinicians and a strong surveillance system. The high proportion of cases in Hispanic patients (51%) is consistent with California demographics.
In many children, the interval between pertussis episodes was only 1-2 years. This was surprising given that duration of protection after natural infection had previously been estimated to be 4-20 years. One possible explanation for this short duration is that there was a pertussis epidemic in California in 2014 (11 203 cases) and the highest number of cases in a nonepidemic year since the 1950s were reported in 2015 (4705 cases) [10] . The majority of episodes (69%) included in this study occurred during these 2 years. It is possible that having 2 back-to-back high-transmission years led to more opportunity for exposure to B. pertussis in a fairly short time interval. In addition, some of the previous studies denoting life-long protection were conducted during the prevaccine era. During this time, there were probably high levels of subclinical boosting in young children. Since the implementation of routine pertussis vaccination, the reduced opportunity for continual subclinical transmission and subsequent boosting has resulted in waning immunity and increased rates of pertussis in adolescents and adults.
Similarly, the interval between most recent vaccination and onset of symptoms was shorter than we expected. Among the 37 pertussis episodes in which the child's most recent pertussis "booster" had been DTaP vaccine (as opposed to natural infection), in 28 episodes (76%) the child had been vaccinated within 2 years of the onset of pertussis symptoms. This is consistent with studies demonstrating rapid waning of immunity from aP vaccines and may indicate that in some circumstances vaccination did not provide even short-term protection against infection [11] .
It is interesting that recurrent pertussis cases were identified in 5 children who were unvaccinated and assumed to be naive to pertussis antigens at the time of their first pertussis infection. This finding was surprising, given previous reports suggesting that priming with natural infection induces life-long sterilizing immunity in vaccine-naive hosts [2, 3] . Four of these cases occurred in children who were <2 months of age at the time of their first pertussis infection. The infant immune system is known to be defective in T-helper (Th) 1-type responses and this may influenced the infants' ability to mount a sterilizing immune response [12] . One of these patients was an unvaccinated 7-year-old who became reinfected about 9 months after her initial pertussis infection. At that time, she presented with typical pertussis, including a cough that lasted >30 days, coughing fits, and posttussive emesis despite treatment. The child was afebrile and had no known history of being immunocompromised. This case seems to be one in which natural infection in a vaccine-naive host failed to induce a sterilizing immune response.
There is an ongoing debate about the nature of the immune response induced by infection with B. pertussis and how vaccination with wP and aP vaccines might modulate this immune response. Recent epidemiological studies from Oregon and Australia demonstrated that infants primed with aP vaccine were at an increased risk of symptomatic pertussis compared with those primed with wP vaccine [13, 14] . In these studies, it seemed that the first vaccine children received (wP or aP) was the most important factor in determining future pertussis risk, regardless of the vaccine used to complete the series.
There is also evidence in both baboons and humans that priming with either aP or wP vaccine modulates the immune response to in vitro pertussis antigens [14, 15] . From a humoral perspective, it has been proposed that priming with aP vaccine might lead to the suppression of antibody responses to nonvaccine pertussis antigens via hypothesized "linked epitope suppression" [15] . Specifically, there is rapid and robust response to vaccine antigens but a dampened response to nonvaccine antigens. From a cell-mediated perspective, it has been demonstrated that priming with wP vaccine induces a predominantly Th1-Th17 response and that priming with aP vaccine induces a predominantly Th2 response that persists until adulthood [12, 16, 17] . Unfortunately, owing to the small number of cases identified in the current study, it was not possible to determine whether priming with aP vaccine made it more or less likely that children would experience a second pertussis episode. Furthermore, our study did not include any children vaccinated with wP vaccine, so no comparison could be made between the role of priming with wP versus aP vaccines.
Given our findings, we propose 4 hypotheses to explain the occurrence of recurrent symptomatic pertussis episodes. First, it is possible that priming with aP vaccines might affect the ability of a child to mount a sterilizing immune response after natural infection when compared to a naive or wP-vaccinated child. This hypothesis is supported by reports in the literature indicating that priming with aP vaccine might result in linked epitope suppression and a skewed Th2 response compared with the Th1-and Th17 response associated with wP vaccination and natural infection. However, the link between these immune modulations and decreased protection against pertussis colonization and/or disease has not been established. Second, it is possible that the children in our study may have unidentified host factors making them uniquely susceptible to pertussis. However, all medical records were reviewed, none of the children had a previously diagnosed immunocompromising condition, and all but 1 were noted to be otherwise healthy.
The third hypothesis is that the children included in this study might have been coinfected with another respiratory pathogen at the time they were diagnosed with pertussis. If this is true, it is possible that it was the other respiratory pathogen that caused the cough illness and that they may have only been asymptomatically infected with B. pertussis. Finally, it is possible that these cases represent examples of latent colonization and reactivation of B. pertussis. This hypothesis is not favored given the overwhelming evidence against latent and chronic carriage of B. pertussis [18] . Unfortunately, the results from this study cannot help discriminate between these various possibilities.
The goal of our study was to investigate recurrent pertussis cases identified through public health surveillance. As a result, the study was also subject to the limitations of surveillance-based reporting, including underreporting and lack of long-term follow-up, and recurrent cases may have been missed owing to misspellings or small errors in data entry. Unlike clinical trials in which all patients with disease are closely monitored, we were unable to obtain detailed information about cough duration limiting our ability to compare severity of disease between cases. Moreover, owing to transitions in California communicable disease surveillance systems, we restricted our study to cases whose episodes both occurred during 2010-2015, which meant we could not draw conclusions about the duration of immunity or capture cases that may have occurred after the study period. Finally, we could not determine which type of aP vaccines each individual received. This is relevant because 2 aP vaccines are currently used in the United States, a vaccine with 3 components and another with 5, and a head-to-head comparison indicated that the 5-component vaccine had greater efficacy [19] .
It is also possible that one of the episodes did not represent a true infection event. This could have been so in the 2 cases in which the PCR result was equivocal but the children met the clinical definitions. In addition, as previously noted, it is possible that these children were coinfected with an asymptomatic case of pertussis and a pathogen that caused a nonpertussis cough illness-in which circumstance the symptoms would have been erroneously attributed to the pertussis infection instead of the other respiratory pathogen. Finally, it is possible that some recurrent cases were a result of false-positive PCR test results caused by contamination. It has been shown that some pertussis vaccines contain PCR-detectable B. pertussis DNA and that accidental transfer of vaccine DNA from environmental surfaces to a clinical specimen can result in a false-positive PCR result [20] . However, it is unlikely that all of the cases identified were due to contamination.
In conclusion, despite its limitations, our study is the first population-based study to document laboratory-confirmed recurrent pertussis episodes in children in the aP vaccine era. Our findings showed that, although rare, recurrent cases of pertussis can occur, and in 1 instance the second episode occurred as early as 89 days after onset of the first episode. We also show that recurrent cases occur among children of all ages and among children who had received ≥3 doses of aP vaccine. The identification of recurrent cases of pertussis in children raises important questions about the duration and nature of immunity provided by natural infection in aP-vaccinated, and unvaccinated children. In particular, a better understanding of how priming with aP vaccine might affect the immune response after exposure to B. pertussis is needed. 
